Skip to content

Study · Non-randomized trial · n = 33 · 2000

13 results

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P

Cancer1 Feb 2000Cited by 173 (Europe PMC)

PMID10679645 (opens in a new tab)DOI10.1002/(sici)1097-0142(20000215)88:4<770::aid-cncr6>3.0.co;2-0 (opens in a new tab)PepBankPUB-10679645
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, quality of life did not differ significantly between lanreotide and octreotide.

    In plain wordsIn carcinoid syndrome, quality of life did not differ significantly between lanreotide and octreotide.

    Peptide
    Lanreotide
    Outcome
    No significant changeQuality of life
    Study

    n = 33

    Comparator
    octreotide
    Outcome group
    Quality of life · Whole body
    Studied dose
    30 mg every 10 days · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    No significant differences were found between lanreotide and octreotide in terms of quality of life.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  2. 02HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, quality of life did not differ significantly between octreotide and lanreotide.

    In plain wordsIn carcinoid syndrome, quality of life did not differ significantly between octreotide and lanreotide.

    Peptide
    Octreotide
    Outcome
    No significant changeQuality of life
    Study

    n = 33

    Comparator
    lanreotide
    Outcome group
    Quality of life · Whole body
    Studied dose
    200 microg twice or thrice daily · subcutaneous · 1 monthAs given in this study (human).

    Source sentences

    Summary
    No significant differences were found between lanreotide and octreotide in terms of quality of life.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  3. 03HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, 68% preferred lanreotide over octreotide (P = 0.03), largely because of simpler administration.

    In plain wordsIn carcinoid syndrome, 68% preferred lanreotide over octreotide, largely because of simpler administration.

    Peptide
    Lanreotide
    Outcome
    IncreasePatient preference
    Study

    n = 33

    Comparator
    octreotide
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    30 mg every 10 days · intramuscular · 1 monthAs given in this study (human).

    Measurements

    Patients preferring lanreotide
    68%
    lanreotide versus octreotide, patient preference
    P value
    0.03 p-value
    preference for lanreotide

    Source sentences

    Summary
    The majority of patients (68%) preferred lanreotide (P = 0.03), largely due to its simplified mode of administration.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  4. 04HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, flushes improved or disappeared in 53.8% (14 of 26) on lanreotide versus 68% (17 of 25) on octreotide.

    In plain wordsIn carcinoid syndrome, flushes improved or disappeared in 53.8% on lanreotide versus 68% on octreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseFlushing improvement or disappearance
    Study

    n: not reported in source

    Comparator
    octreotide
    Outcome group
    Carcinoid symptoms · Gastrointestinal
    Studied dose
    30 mg every 10 days · intramuscular · 1 monthAs given in this study (human).

    Measurements

    Patients with flush disappearance or improvement
    53.8%
    lanreotide, 14 of 26 patients
    Patients with flush disappearance or improvement
    68%
    octreotide, 17 of 25 patients

    Source sentences

    Summary
    Disappearance or improvement in flushes occurred in 53.8% of patients (14 of 26) while on lanreotide and in 68% (17 of 25) on octreotide.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  5. 05HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, flushes improved or disappeared in 68% (17 of 25) on octreotide versus 53.8% (14 of 26) on lanreotide.

    In plain wordsIn carcinoid syndrome, flushes improved or disappeared in 68% on octreotide versus 53.8% on lanreotide.

    Peptide
    Octreotide
    Outcome
    IncreaseFlushing improvement or disappearance
    Study

    n: not reported in source

    Comparator
    lanreotide
    Outcome group
    Carcinoid symptoms · Gastrointestinal
    Studied dose
    200 microg twice or thrice daily · subcutaneous · 1 monthAs given in this study (human).

    Measurements

    Patients with flush disappearance or improvement
    68%
    octreotide, 17 of 25 patients
    Patients with flush disappearance or improvement
    53.8%
    lanreotide, 14 of 26 patients

    Source sentences

    Summary
    Disappearance or improvement in flushes occurred in 53.8% of patients (14 of 26) while on lanreotide and in 68% (17 of 25) on octreotide.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  6. 06HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, diarrhea improved or disappeared in 45.4% (10 of 22) on lanreotide versus 50% (11 of 22) on octreotide.

    In plain wordsIn carcinoid syndrome, diarrhea improved or disappeared in 45.4% on lanreotide versus 50% on octreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseDiarrhea improvement or disappearance
    Study

    n: not reported in source

    Comparator
    octreotide
    Outcome group
    Carcinoid symptoms · Gastrointestinal
    Studied dose
    30 mg every 10 days · intramuscular · 1 monthAs given in this study (human).

    Measurements

    Patients with diarrhea disappearance or improvement
    45.4%
    lanreotide, 10 of 22 patients
    Patients with diarrhea disappearance or improvement
    50%
    octreotide, 11 of 22 patients

    Source sentences

    Summary
    A disappearance or improvement of diarrhea in 45.4% (10 of 22) on lanreotide, compared with 50% (11 of 22) on octreotide, was also observed.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  7. 07HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, diarrhea improved or disappeared in 50% (11 of 22) on octreotide versus 45.4% (10 of 22) on lanreotide.

    In plain wordsIn carcinoid syndrome, diarrhea improved or disappeared in 50% on octreotide versus 45.4% on lanreotide.

    Peptide
    Octreotide
    Outcome
    IncreaseDiarrhea improvement or disappearance
    Study

    n: not reported in source

    Comparator
    lanreotide
    Outcome group
    Carcinoid symptoms · Gastrointestinal
    Studied dose
    200 microg twice or thrice daily · subcutaneous · 1 monthAs given in this study (human).

    Measurements

    Patients with diarrhea disappearance or improvement
    50%
    octreotide, 11 of 22 patients
    Patients with diarrhea disappearance or improvement
    45.4%
    lanreotide, 10 of 22 patients

    Source sentences

    Summary
    A disappearance or improvement of diarrhea in 45.4% (10 of 22) on lanreotide, compared with 50% (11 of 22) on octreotide, was also observed.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  8. 08HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, lanreotide and octreotide were equally effective in reducing urinary 5HIAA.

    In plain wordsIn carcinoid syndrome, lanreotide and octreotide reduced urinary 5HIAA equally.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedUrinary 5HIAA
    Study

    n: not reported in source

    Comparator
    octreotide
    Outcome group
    Cancer biomarkers and prognosis · Gastrointestinal
    Studied dose
    30 mg every 10 days · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    Lanreotide and octreotide were equally effective in reducing urinary 5HIAA levels and plasma serotonin levels.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  9. 09HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, octreotide and lanreotide were equally effective in reducing urinary 5HIAA.

    In plain wordsIn carcinoid syndrome, octreotide and lanreotide reduced urinary 5HIAA equally.

    Peptide
    Octreotide
    Outcome
    Direction not reportedUrinary 5HIAA
    Study

    n: not reported in source

    Comparator
    lanreotide
    Outcome group
    Cancer biomarkers and prognosis · Gastrointestinal
    Studied dose
    200 microg twice or thrice daily · subcutaneous · 1 monthAs given in this study (human).

    Source sentences

    Summary
    Lanreotide and octreotide were equally effective in reducing urinary 5HIAA levels and plasma serotonin levels.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  10. 10HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, lanreotide and octreotide were equally effective in reducing plasma serotonin.

    In plain wordsIn carcinoid syndrome, lanreotide and octreotide reduced blood serotonin equally.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedPlasma serotonin
    Study

    n: not reported in source

    Comparator
    octreotide
    Outcome group
    Cancer biomarkers and prognosis · Gastrointestinal
    Studied dose
    30 mg every 10 days · intramuscular · 1 monthAs given in this study (human).

    Source sentences

    Summary
    Lanreotide and octreotide were equally effective in reducing urinary 5HIAA levels and plasma serotonin levels.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  11. 11HumanNon-randomized trialEfficacy outcome

    In carcinoid syndrome, octreotide and lanreotide were equally effective in reducing plasma serotonin.

    In plain wordsIn carcinoid syndrome, octreotide and lanreotide reduced blood serotonin equally.

    Peptide
    Octreotide
    Outcome
    Direction not reportedPlasma serotonin
    Study

    n: not reported in source

    Comparator
    lanreotide
    Outcome group
    Cancer biomarkers and prognosis · Gastrointestinal
    Studied dose
    200 microg twice or thrice daily · subcutaneous · 1 monthAs given in this study (human).

    Source sentences

    Summary
    Lanreotide and octreotide were equally effective in reducing urinary 5HIAA levels and plasma serotonin levels.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  12. 12HumanNon-randomized trialSafety outcome

    In carcinoid syndrome, mild abdominal pain and nausea occurred in 14% receiving lanreotide versus 29% receiving octreotide, without separate symptom rates.

    In plain wordsIn carcinoid syndrome, combined mild abdominal pain and nausea occurred in 14% on lanreotide versus 29% on octreotide.

    Peptide
    Lanreotide
    Outcome
    DecreaseCombined abdominal pain and nausea
    Study

    n: not reported in source

    Comparator
    octreotide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    30 mg every 10 days · intramuscular · 1 monthAs given in this study (human).

    Measurements

    Patients with mild abdominal pain and nausea (combined)
    14%
    lanreotide
    Patients with mild abdominal pain and nausea (combined)
    29%
    octreotide

    Source sentences

    Summary
    Both treatments were well tolerated, with mild symptoms of abdominal pain and nausea observed in 29% and 14% receiving octreotide and lanreotide, respectively.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.
  13. 13HumanNon-randomized trialSafety outcome

    In carcinoid syndrome, mild abdominal pain and nausea occurred in 29% receiving octreotide versus 14% receiving lanreotide, without separate symptom rates.

    In plain wordsIn carcinoid syndrome, combined mild abdominal pain and nausea occurred in 29% on octreotide versus 14% on lanreotide.

    Peptide
    Octreotide
    Outcome
    IncreaseCombined abdominal pain and nausea
    Study

    n: not reported in source

    Comparator
    lanreotide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    200 microg twice or thrice daily · subcutaneous · 1 monthAs given in this study (human).

    Measurements

    Patients with mild abdominal pain and nausea (combined)
    29%
    octreotide
    Patients with mild abdominal pain and nausea (combined)
    14%
    lanreotide

    Source sentences

    Summary
    Both treatments were well tolerated, with mild symptoms of abdominal pain and nausea observed in 29% and 14% receiving octreotide and lanreotide, respectively.
    2 context sentences
    Summary · context
    Thirty-three patients with carcinoid syndrome were included in an open, multicenter, crossover study.
    Summary · context
    Half of the patients received octreotide 200 microg subcutaneously twice or thrice daily for 1 month followed by lanreotide 30 mg intramuscularly every 10 days for 1 month, while the other half commenced with lanreotide followed by octreotide in a similar fashion.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownEarly phase 1NCT02823691

The MetNET-2 Trial

Fondazione IRCCS Istituto Nazionale dei Tumori, Milanon = 20Apr 2016 to est. Dec 2021

Neuroendocrine Tumors

Trial pageClinicalTrials.govUpdated 7 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.